NYSE · MYOV
Healthcare · Biotechnology
$26.98
Down-$0.01 (-0.04%)
Updated Aug 15, 2026, 2:58 PM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
MYOV does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning MYOV.
MYOV research
Company profile and research snapshot.
Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It is also developing MVT-602, an oligopeptide kisspeptin agonist, which is in Phase II clinical trial for the treatment of female infertility as part of assisted reproduction. Myovant Sciences Ltd. has collaboration with Pfizer Inc. to develop and commercialize relugolix in oncology and women's health. The company was formerly known as Roivant Endocrinology Ltd. and changed its name to Myovant Sciences Ltd. in May 2016. The company was incorporated in 2016 and is based in London, the United Kingdom. Myovant Sciences Ltd. is a subsidiary of Sumitovant Biopharma Ltd.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 26, 2022 | Evercore ISI Group | In-Line | — |
| Oct 25, 2022 | SVB Leerink | Market Perform | — |
| Oct 24, 2022 | Baird | Neutral | — |
| Aug 9, 2022 | SVB Leerink | Outperform | — |
| Jul 28, 2022 | Goldman Sachs | Neutral | — |
No generated briefing is available yet.
GlobeNewswire Inc. · Jan 26, 2023
BASEL, Switzerland, Jan. 26, 2023 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a biopharmaceutical company that aspires to redefine care for women and men through purpose-driven science, empowering medicines, and transformative advocacy, today announced financial results for the third quarter of fiscal year 2022 and provided other corporate updates.
GlobeNewswire Inc. · Nov 16, 2022
BASEL, Switzerland, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a biopharmaceutical company that aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy, today announced that it approved equity awards for 18 new employees with a grant date of November 15, 2022 pursuant to Myovant’s 2020 Inducement Plan. The equity awards were granted to the employees joining Myovant in accordance with NYSE’s Listed Company Manual Rule 303A.08.
GlobeNewswire Inc. · Nov 16, 2022
BASEL, Switzerland, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) today announced the appointment of Ann Tomlin as Senior Vice President of Human Resources. Beginning November 28, Ms. Tomlin will be responsible for developing talent solutions and human resources strategies across Myovant’s global functions. She will serve as a member of the Executive Committee and will report to David Marek, Myovant’s Chief Executive Officer.
Benzinga · Oct 26, 2022
Upgrades For Enterprise Financial Services Corp (NASDAQ:EFSC), DA Davidson upgraded the previous rating of Neutral to Buy. For the third quarter, Enterprise Finl Servs had an EPS of $1.32, compared to year-ago quarter EPS of $1.27. The stock has a 52-week-high of $51.50 and a 52-week-low of $39.63. At the end of the last trading period, Enterprise Finl Servs closed at $50.84. Goldman Sachs upgraded the previous rating for Biogen Inc (NASDAQ:BIIB) from Neutral to Buy. For the third quarter, Biogen had an EPS of $4.77, compared to year-ago quarter EPS of $4.77. At the moment, the stock has a 52-week-high of $283.44 and a 52-week-low of $187.16. Biogen closed at $273.56 at the end of the last trading period. According to CJS Securities, the prior rating for Vicor Corp (NASDAQ:VICR) was changed from Market Perform to Market Outperform. Vicor earned $0.18 in the third quarter, compared to $0.29 in the year-ago quarter. At the moment, the stock has a 52-week-high of $128.96 and a 52-week-low of $42.90. Vicor closed at $48.62 at the end of the last trading period. For Agilysys Inc (NASDAQ:AGYS), Craig-Hallum upgraded the previous rating of Hold to Buy. For the second quarter, Agilysys had an EPS of $0.24, compared to year-ago quarter EPS of $0.18. The current stock performance of Agilysys shows a 52-week-high of $57.45 and a 52-week-low of $31.49. Moreover, at the end of the last trading period, the closing price was at $54.86. For Range Resources Corp (NYSE:RRC), Susquehanna upgraded the previous rating of Neutral to Positive. Range Resources earned $1.37 in the third quarter, compared to $0.52 in the year-ago quarter. The stock has a 52-week-high of $37.44 and a 52-week-low of $16.71. At the end of the last trading period, Range Resources closed at $28.60. For Liberty Energy Inc (NYSE:LBRT), Wells Fargo upgraded the previous rating of Equal-Weight to Overweight. In the third quarter, Liberty Energy showed an EPS of $0.78, compared to $0.22 from the year-ago quarter. The stock has a 52-week-high of $20.05 and a 52-week-low of $9.74. At the end of the last trading period, Liberty Energy closed at $15.85. For Humana Inc (NYSE:HUM), Deutsche Bank upgraded the previous rating of Hold to Buy. Humana earned $8.67 in the second quarter, compared to $6.89 in the year-ago quarter. The stock has a 52-week-high of $540.20 and a 52-week-low of $351.20. At the end of the last trading period, Humana closed at $529.46. BTIG upgraded the previous rating for Helix Energy Solutions Group Inc (NYSE:HLX) from Neutral to Buy. In the third quarter, Helix Energy Solutions Gr showed an EPS of $0.12, compared to $0.13 from the year-ago quarter. The current stock performance of Helix Energy Solutions Gr shows a 52-week-high of $5.78 and a 52-week-low of $2.47. Moreover, at the end of the last trading period, the closing price was at $5.18. According to Morgan Stanley, the prior rating for Discover Financial Services (NYSE:DFS) was changed from Equal-Weight to Overweight. Discover Financial earned $3.54 in the third quarter, compared to $3.54 in the year-ago quarter. The current stock performance of Discover Financial shows a 52-week-high of $130.81 and a 52-week-low of $87.64. Moreover, at the end of the last trading period, the closing price was at $99.97. According to Wells Fargo, the prior rating for Halliburton Co (NYSE:HAL) was changed from Equal-Weight to Overweight. In the third quarter, Halliburton showed an EPS of $0.60, compared to $0.28 from the year-ago quarter. At the moment, the stock has a 52-week-high of $43.99 and a 52-week-low of $23.01. Halliburton closed at $34.98 at the end of the last trading period. See all analyst ratings upgrades. Downgrades According to Fox Advisors, the prior rating for Corning Inc (NYSE:GLW) was changed from Overweight to Equal-Weight. ...Full story available on Benzinga.com
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning MYOV.
No results
No recent SID articles mention MYOV.
